Continuous Dentoalveolar Neuropathic Pain Response to Repeated Intravenous Ketamine Infusions: A Case Report

This article describes a case of continuous dentoalveolar neuropathic pain in which relief was obtained following repeated administration of intravenous infusions of a subanesthetic dose of ketamine. A 50-year-old female presented in 2006 with a 1-year history of constant sharp pain in the gingiva surrounding the maxillary left second premolar and second molar rated as 10/10 on a pain intensity scale. After multiple systemic medications failed to adequately manage the patient’s pain, partial pain reduction was obtained (4/10) with daily use of methadone 50 mg in combination with application of a topical compound including lidocaine, amitriptyline, and carbamazepine to the affected area as needed. In July 2012, for reasons unrelated to the neuropathic pain condition, the patient underwent extraction of the maxillary right second premolar under intravenous sedation. Initially, a subanesthetic dose of ketamine was added to the sedation regimen for postoperative pain management; however, due to subsequent improvement of the dentoalveolar neuropathic pain, repeated intravenous infusions were recommended for further pain management. The patient’s neuropathic pain condition was successfully managed by a total of five intravenous ketamine infusions repeated over a 4-year period of time. The patient’s daily use of methadone was progressively reduced and finally discontinued. This case suggests a possible role for intravenous infusions of subanesthetic doses of ketamine as an adjuvant management option in patients suffering from intractable dentoalveolar continuous neuropathic pain conditions.

continuous neuropathic pain;ketamine;NMDA receptor;opioid tolerance;orofacial pain

1.Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015;14:162–173.

2.Liedgens H, Obradovic M, De Courcy J, Holbrook T, Jakubanis R. A burden of illness study for neuropathic pain in Europe. Clinicoecon Outcomes Res 2016;8:113–126.

3.van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain 2014;155:654–662.

4.International Association for the Study of Pain. IASP Taxonomy (2012). http://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698&navItemNumber=576. Accessed 21 February 2018.

5.Okeson JP. Bell’s Oral and Facial Pain, ed 7. Chicago: Quintessence, 2014.

6.De Leeuw R, Klasser GD. Orofacial Pain: Guidelines for Assess-ment, Diagnosis, and Management, ed 5. Chicago: Quintes-sence, 2013.

7.Headache Classification Committee of the International Head-ache Society (IHS). The International Classification of Head-ache Disorders, 3rd edition (beta version). Cephalalgia 2013;33: 629–808.

8.Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: Facts and fiction. Cephalalgia 2017:37:670–679.

9.Nixdorf DR, Moana-Filho EJ, Law AS, McGuire LA, Hodges JS, John MT. Frequency of nonodontogenic pain after endodon-tic therapy: A systematic review and meta-analysis. J Endod 2010;36:1494–1498.

10.Klasser GD, Kugelmann AM, Villines D, Johnson BR. The prev-alence of persistent pain after nonsurgical root canal treatment. Quintessence Int 2011;42:259–269.

11.Okeson J, Bell WE. Bell’s Orofacial Pains: The Clinical Management of Orofacial Pain, ed 6. Chicago: Quintessence, 2005.

12.Gilron I, Baron R, Jensen T. Neuropathic pain: Principles of diag-nosis and treatment. Mayo Clin Proc 2015;90:532–545.

13.Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009;9:71–78.

14.Sessle BJ. Peripheral and central mechanisms of orofacial in-flammatory pain. Int Rev Neurobiol 2011;97:179–206.

15.Baron R, Binder A, Wasner G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807–819.

16.Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009;139:267–284.

17.Hocking G, Visser EJ, Schug SA, Cousins MJ. Ketamine: Does life begin at 40? Pain Clin Updates 2007;15:1–6.

18.Kawamata T, Omote K, Sonoda H, Kawamata M, Namiki A. Analgesic mechanisms of ketamine in the presence and absence of peripheral inflammation. Anesthesiology 2000;93:520–528.

19.Elia N, Tramèr MR. Ketamine and postoperative pain—A quantita-tive systematic review of randomised trials. Pain 2005;113:61–70.

20.De Kock M, Lavand’homme P, Waterloos H. ‘Balanced analge-sia’ in the perioperative period: Is there a place for ketamine?Pain 2001;92:373–380.

21.Shah A, Halli R, Merchant Y, Kshirsagar R, Khurana J. Efficacy of ketamine as an adjunct to local anesthesia in the surgical removal of impacted mandibular third molars-A split mouth prospective controlled clinical study. J Clin Diagn Res 2016;10:ZC29–ZC33.

22. Garip H, Satılmıs¸ K. Effects of midazolam/low-do e ketamine conscious intravenous sedation on pain, swelling, and trismus after surgical extraction of third molars. J Oral Maxillofac Surg 2011;69:1023–1030.

23.Aydin ON, Ugur B, Ozgun S, Eyigör H, Copcu O. Pain preven-tion with intraoperative ketamine in outpatient children undergo-ing tonsillectomy or tonsillectomy and adenotomy. J Clin Anesth 2007;19:115–119.

24.Bilgin H, Ozcan B, Bilgin T, et al. The influence of timing of sys-temic ketamine administration on postoperative morphine con-sumption. J Clin Anesth 2005;17:592–597.

25.Rakic AM, Golembiewski J. Low-dose ketamine infusion for post-operative pain management. J Perianesth Nurs 2009;24:254–257.

26.Wang X, Xie H, Wang G. Improved postoperative analgesia with coadministration of preoperative epidural ketamine and midazol-am. J Clin Anesth 2006;18:563–569.

27.Mitterauer BJ. Ketamine may block NMDA receptors in astro-cytes causing a rapid antidepressant effect. Front Synaptic Neurosci 2012;4:8.

28.do Vale EM, Xavier CC, Nogueira BG, et al. Antinociceptive and anti-inflammatory effects of ketamine and the relationship to its antidepressant action and GSK3 inhibition. Basic Clin Pharmacol Toxicol 2016;119:562–573.

29.De Kock M, Loix S, Lavand’homme P. Ketamine and peripheral inflammation. CNS Neurosci Ther 2013;19:403–410.

30.Prommer EE. Ketamine for pain: An update of uses in palliative care. J Palliat Med 2012;15:474–483.

31.Pigg M, Svensson P, Drangsholt M, List T. Seven-year follow-up of patients diagnosed with atypical odontalgia: A prospective study. J Orofac Pain 2013;27:151–164.

32.Smith HS. Opioids and neuropathic pain. Pain Physician 2012;15(suppl):ES93–ES110.

33.Célèrier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia in-duced by fentanyl in rats: Preventive effect of ketamine. Anesthe-siology 2000;92:465–472.

34.Weinbroum AA. Non-opioid IV adjuvants in the perioperative period: Pharmacological and clinical aspects of ketamine and gabapentinoids. Pharmacol Res 2012;65:411–429.

35.Kronenberg RH. Ketamine as an analgesic: Parenteral, oral, rec-tal, subcutaneous, transdermal and intranasal administration. J Pain Palliat Care Pharmacother 2002;16:27–35.

36.Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother 2006;60:341–348.

37.Matsuura N, Shibukawa Y, Kato M, Ichinohe T, Suzuki T, Kaneko Y. Ketamine, not fentanyl, suppresses pain-related magnet-ic fields associated with trigeminally innervated area following CO2 laser stimulation. Neurosci Res 2008;62:105–111.

38. Cairns BE, Svensson P, Wang K, et al. Ketamine attenuates glu-tamate-induced mechanical sensitization of the masseter mus-cle in human males. Exp Brain Res 2006;169:467–472.

39. Chizh BA. Low dose ketamine: A therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plas-ticity in pain pathways. J Psychopharmacol 2007;21:259–271.

40.Castrillon EE, Cairns BE, Ernberg M, et al. Effect of periph-eral NMDA receptor blockade with ketamine on chronic myofascial pain in temporomandibular disorder patients: A ran-domized, double-blinded, placebo-controlled trial. J Orofac Pain 2008;22:122–130.

41.Ahern TL, Herring AA, Miller S, Frazee BW. Low-dose ketamine infusion for emergency department patients with severe pain. Pain Med 2015;16:1402–1409.

42.Ahern TL, Herring AA, Anderson ES, Madia VA, Fahimi J, Frazee BW. The first 500: Initial experience with widespread use of low-dose ketamine for acute pain management in the ED. Am J Emerg Med 2015;33:197–201.

43.Radvansky BM, Puri S, Sifonios AN, Eloy JD, Le V. Ketamine—A narrative review of its uses in medicine. Am J Ther 2016;23:e1414–e1426.

44.Bell RF. Ketamine for chronic non-cancer pain. Pain 2009;141: 210–214.

45.Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246–252.

46.Lauretti GR, Gomes JM, Reis MP, Pereira NL. Low doses of epi-dural ketamine or neostigmine, but not midazolam, improve mor-phine analgesia in epidural terminal cancer pain therapy. J Clin Anesth 1999;11:663–668.

47.Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adju-vants to oral morphine therapy for cancer pain management. Anesthesiology 1999;90:1528–1533.

48.Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produc-es effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009;145:304–311.

49.Sheehy KA, Muller EA, Lippold C, Nouraie M, Finkel JC, Quezado ZM. Subanesthetic ketamine infusions for the treat-ment of children and adolescents with chronic pain: A longitudi-nal study. BMC Pediatr 2015;15:198.

50.Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T. Rapid antidepressant effect of ketamine anesthesia during elec-troconvulsive therapy of treatment-resistant depression: Comparing ketamine and propofol anesthesia. J ECT 2010;26:223–227.

51.Eide PK, Jørum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid re-ceptor antagonist ketamine: A double-blind, cross-over compar-ison with morphine and placebo. Pain 1994;58:347–354.

52.Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: A preliminary study. Pain 1994;56:51–57.

53.Marchetti F, Coutaux A, Bellanger A, Magneux C, Bourgeois P, Mion G. Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 pa-tients. Eur J Pain 2015;19:984–993.

54.Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: A 5-year retrospective analy-sis. Pain Med 2012;13:263–269.

55.Quinlan J. The use of a subanesthetic infusion of intravenous ketamine to allow withdrawal of medically prescribed opioids in people with chronic pain, opioid tolerance and hyperalgesia: Outcome at 6 months. Pain Med 2012;13:1524–1525.

56.Mathisen LC, Skjelbred P, Skoglund LA, Oye I. Effect of ket-amine, an NMDA receptor inhibitor, in acute and chronic orofa-cial pain. Pain 1995;61:215–220.

57.Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: A promising therapy in need of optimization. Anesth Analg 2017;124:661–674.

58.Noppers I, Niesters M, Swartjes M, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibro-myalgia pain: A randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain 2011;15:942–949.

59.Amin P, Roeland E, Atayee R. Case report: Efficacy and tolera-bility of ketamine in opioid-refractory cancer pain. J Pain Palliat Care Pharmacother 2014;28:233–242.

60.Schoevers RA, Chaves TV, Balukova SM, Rot MA, Kortekaas R. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry 2016;208:108–113.

61.Rabben T, Skjelbred P, Oye I. Prolonged analgesic effect of ket-amine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther 1999;289:1060–1066.

62.Rabben T, Øye I. Interindividual differences in the analgesic re-sponse to ketamine in chronic orofacial pain. Eur J Pain 2001;5: 233–240.

63.Douglas SR, Shenoda BB, Qureshi RA, et al. Analgesic re-sponse to intravenous ketamine is linked to a circulating microR-NA signature in female patients with Complex Regional Pain Syndrome. J Pain 2015;16:814–824.

64.Gönül O, Satilmis¸ T, Ciftci A, Sipahi A, Garip H, Göker K. Comparison of the effects of topical ketamine and tramadol on postoperative pain after mandibular molar extraction. J Oral Maxillofac Surg 2015;73:2103–2107.

65.Aigbedia SO, Tobi KU, Amadasun FE. A comparative study of ketamine gargle and lidocaine jelly application for the prevention of postoperative throat pain following general anaesthesia with endotracheal intubation. Niger J Clin Pract 2017;20:677–685.

66.Mitchell AC. An unusual case of chronic neuropathic pain re-sponds to an optimum frequency of intravenous ketamine infu-sions. J Pain Symptom Manage 2001;21:443–446.